Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Crizanlizumab-tmca (Adakveo) is indicated to reduce the frequency of vasoocclusive crises in adults and pediatric patients aged 16 years and older with sickle cell disease.
• The information was derived from a total of 5 systematic reviews/meta-analyses studies.
• In comparison to other drugs, crizanlizumab demonstrated significant efficacy by reducing VOC incidence by up to 45% at higher doses, prolonging median time to first and second VOCs, and showing benefits across subgroups including those using hydroxyurea or having various SCD genotypes.
• Safety profiles for crizanlizumab were comparable to placebo across studies; pain was noted as a common side effect but generally well-tolerated without significant differences in adverse events compared to placebo.
• Subgroup considerations highlighted that crizanlizumab's effectiveness spans multiple patient demographics within the SCD population, making it versatile for broader clinical application while ongoing trials aim at evaluating its use further in pediatric patients and other complications related to SCD.
• Compared with L-glutamine, which also reduced VOCs effectively when used alone or synergistically with voxelotor, voxelotor itself did not significantly reduce VOC occurrences but increased hemoglobin levels. Antiplatelet agents like prasugrel showed mixed results indicating limited evidence on their benefit for preventing VOEs.